Prensa LatinaLab Grown Human Colons Made Out of Stem CellsPrensa LatinaWashington, Jun 27 (Prensa Latina) Scientists used human pluripotent stem cells to generate human embryonic colons in a laboratory that function much like natural human tissues when… Continue reading
CAR-T Value Calculation In The Firing LineSeeking AlphaThrowing a serious spanner into the assessment of these CAR-T therapies compared with standard small-molecule drugs or biologicals, however, is the fact that for now they are frequently a bridge to… Continue reading
EurekAlert (press release)New book on Synthetic Biology from Cold Spring Harbor Laboratory PressEurekAlert (press release)Cold Spring Harbor, NY — Cold Spring Harbor Laboratory Press (CSHLP) today announced the release of Synthetic Biology: Tools for … Continue reading
Curetoday.comPARP Inhibitors Plus Immunotherapy May Be the Future in Ovarian CancerCuretoday.comThe future of treating ovarian cancer may lie in combinations of immunotherapy plus PARP inhibitors, says Samir N. Khleif, M.D.. Alternatives to chemotherap… Continue reading
|
DuPont Pioneer Licenses CRISPR Tech From ERS Genomics
GenomeWeb NEW YORK (GenomeWeb) – DuPont Pioneer has signed an agreement to acquire the exclusive rights to ERS Genomics’ portfolio of CRISPR-Cas genome-editing technologies for all plant and agricultural applications, the companies announced today. DuPont Pioneer Secures Exclusive Rights to ERS Genomics’ CRISPR-Cas Patent Portfolio for AgriculturePR Web (press release) |
|
Epigenetic Reprogramming May Boost Immunotherapy
Genetic Engineering & Biotechnology News Even when immunotherapy “takes the brakes off” a cancer patient’s immune cells, these cells may remain stuck in neutral, or they may act as though they are out of gas, exhausted. Immunotherapy, then, may need to rejuvenate immune cells, specifically T … |
FiercePharma |
Takeda positioning itself to assume EU stem cell production within 5 years
FiercePharma Takeda Pharma is positioning itself to take over stem cell production in Europe from its partner TiGenix by 2021 after Swissmedic—the Swiss Agency for Therapeutic Products—said last week it has accepted for review the file for an investigational drug … |